GILD vs. BIIB, NBIX, TECH, QGEN, RGEN, CRSP, DNLI, AMGN, MRNA, and BNTX
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Biogen (BIIB), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Amgen (AMGN), Moderna (MRNA), and BioNTech (BNTX). These companies are all part of the "biological products, except diagnostic" industry.
Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.
Biogen has a net margin of 12.07% compared to Biogen's net margin of 1.76%. Biogen's return on equity of 24.34% beat Gilead Sciences' return on equity.
Biogen currently has a consensus price target of $288.46, indicating a potential upside of 25.11%. Gilead Sciences has a consensus price target of $83.69, indicating a potential upside of 23.58%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Biogen is more favorable than Gilead Sciences.
Gilead Sciences received 673 more outperform votes than Biogen when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 71.89% of users gave Biogen an outperform vote.
87.9% of Biogen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Biogen shares are held by company insiders. Comparatively, 0.2% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Gilead Sciences has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biogen had 14 more articles in the media than Gilead Sciences. MarketBeat recorded 29 mentions for Biogen and 15 mentions for Gilead Sciences. Biogen's average media sentiment score of 0.55 beat Gilead Sciences' score of 0.34 indicating that Gilead Sciences is being referred to more favorably in the news media.
Biogen has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
Summary
Biogen and Gilead Sciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gilead Sciences Competitors List
Related Companies and Tools
